Company profile
Nanobiotix S.A.
NASDAQ:NBTXBiotechnology: Pharmaceutical Preparations
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03589339 | phase1 | active_not_recruiting | 2019-01-16 | 2027-04-30 | Nanobiotix | NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy |
| NCT02805894 | phase1_2 | terminated | 2017-11-15 | 2020-03-19 | Nanobiotix | NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma |
FDA applications (0)
No records yet.